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Abstract
Background Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate 
the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated 
ketamine administration could be a viable strategy to maintain treatment gains.
Methods Electronic databases (Medline via PubMed, Embase, Cochrane Library, Trip Database) were systematically 
searched until February 22, 2019, for published peer-reviewed randomized controlled trials (RCTs) concerning a single 
and repeated administration of ketamine in patients with major depression. All relevant RCTs were selected and critically 
appraised, and a meta-analysis of eligible studies was performed.
Results A total of 20 studies were included in the meta-analysis. The largest effect of ketamine vs. controls in reducing 
depressive symptoms was observed at 24 h (SMD = − 0.89; 95% CI − 1.24; − 0.53; p < 0.00001); however, a significant 
difference was shown for up to 7 days after a single dose. Significant differences compared with controls were observed for 
up to 7 days in treatment-resistant patients and when ketamine was added to ongoing antidepressant treatment, while there 
were no significant differences at 7 days when ketamine was used as monotherapy. In patients with major depression, initial 
antidepressant effects of ketamine were maintained during repeated dosing. At 2–3 weeks of repeated ketamine treatment, 
significant reduction of depression severity scores was observed: SMD = − 0.70; 95% CI − 1.15; − 0.25 or SMD = − 0.81; 
95% CI − 1.41; − 0.20 (depending on the dosing regimen used); p ≤ 0.009 vs placebo.
Conclusions Our meta-analysis revealed rapid and robust antidepressant effects of single-dose ketamine in patients with 
treatment-resistant depression (TRD). By pooling data from RCTs, we showed for the first time that repeated ketamine 
administration is effective in sustaining initial antidepressant effects observed after single dosing.
Keywords Ketamine · Antidepressants · Major depressive disorder · Bipolar disorder · Meta-analysis · RCT 
Introduction
Depression is a common mental disorder and a leading 
cause of disability worldwide [1]. According to World 
Health Organization data, more than 264 million people 
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globally are affected by depression, and the disease bur-
den has been increasing worldwide [2]. There are a num-
ber of well-established treatments for major depressive 
disorder (MDD), but they are only partially effective or 
even not effective at all in a significant number of patients 
[3]. Despite multiple treatment approaches, about 30% of 
patients with MDD do not respond to conventional antide-
pressants and remain symptomatic [3]. Another limitation 
of the existing antidepressants is a delayed onset of action 
[4], which can result in treatment cessation and increased 
suicidal risk in some patients [3, 5]. As a consequence, 
there is a critical need for new rapidly acting and effec-
tive treatment options for people with both unipolar and 
bipolar depression.
Ketamine is a noncompetitive N-methyl-d-aspartate 
glutamate receptor antagonist originally approved for use 
as an anesthetic. In 2000, Berman et al. [6], for the first 
time showed rapid and robust antidepressant effects of 
single-dose ketamine, confirmed later in numerous clini-
cal studies among patients with major depression [7–9]. 
Importantly, ketamine is effective also in treatment-
resistant depression (TRD), which is mostly defined as 
lack of response to at least two different antidepressant 
drugs at an adequate dose and duration of administration 
[10]. However, antidepressant effects of single ketamine 
administration are short lived, and the average duration 
of response after a single dose is around 1 week [11]. 
Data from open-label studies showed promising results of 
repeated ketamine administration [12, 13] and a trend to 
a more pronounced reduction in depression severity after 
successive ketamine infusions [14, 15]. In 2018, the first 
results of research on repeated intranasal administration 
of esketamine (the S-enantiomer of ketamine) has shown 
a significant improvement of depressive symptoms in 
patients with TRD, which has been sustained for up to 
9 weeks of treatment [16].
Ketamine effects in depression have been studied in 
previous meta-analyses [11, 17–19]. However, in the 
last few years, new randomized controlled trials (RCTs) 
regarding ketamine use in major depression have been 
conducted, some of which assessed repeated ketamine 
administration. Due to a growing body of evidence from 
RCTs, there is a need for a meta-analysis that would elu-
cidate the antidepressant effects of ketamine in selected 
groups of patients (e.g., TRD, patients treated with keta-
mine alone or in combination with ongoing antidepressant 
treatment) as well as establish whether repeated ketamine 




A systematic review was performed using the following 
databases: Embase, Medline (via PubMed), Cochrane Cen-
tral, and Trip Database until February 22, 2019. The search 
strategy was based on the MeSH (medical subject heading) 
terms and Emtree, combined with Boole’s logical opera-
tors with major search terms “ketamine” AND “depression” 
(Table 1) and supplemented with hand-searching reference 
lists of identified studies. Clinical trials registries (www.
clini caltr ials.gov, www.clini caltr ialsr egist er.eu), identified 
systematic reviews, and meta-analyses were also searched 
for relevant data.
Selection criteria
Two independent contributors (J.K. and A.M.M.) used the 
same search strategy to identity relevant clinical trials. All 
disagreements were resolved by discussion with the third 
author (P.K.) to reach consensus. The study selection was 
based on the titles and abstracts, and, finally, on full-text 
articles. The meta-analysis included RCTs comparing keta-
mine with placebo or “active placebo” (non-antidepressant 
anesthetic) in patients with major depression. All relevant 
RCTs were selected and critically appraised according to the 
Table 1  MeSH subject headings and EMTREE keywords used in search strategy construction (last updated: 22.02.2019)
Keywords (combined with boolean logical operators: AND, OR)
Medical condition (Depressive Disorders) OR (Depressive Disorder) OR (Depressive Neurosis) OR (Depressive Neuroses) OR (Endog-
enous Depression) OR (Endogenous Depressions) OR (Depressive Syndrome) OR (Depressive Syndromes) OR 
Depression OR (Neurotic Depression) OR (Neurotic Depressions) OR Melancholia OR Melancholias OR (Unipolar 
Depression) OR (Unipolar Depressions) OR Bipolar Disorder OR MDD OR (Major Depressive Disorders) OR 
(Major Depressive Disorder)
Intervention (Ketamine Hydrochloride) OR Ketamine OR Calipsol OR Kalipsol OR Calypsol OR Ketalar OR Ketaset OR Ketanest 
OR CI-581 OR CI 581 OR CI581
Methodological limits PubMed: Humans, Controlled Clinical Trial, Randomized Controlled Trial EMBASE: Humans, Controlled Clinical 
Trial, Randomized Controlled Trial CENTRAL: Cochrane Central Register of Controlled Trials, Word variations 
have been searched
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Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [20]. The following criteria 
were used for study inclusion: (1) RCTs (crossover or paral-
lel) assessing more than 5 patients; (2) adult patients treated 
for major depression (unipolar or bipolar, treatment-resistant 
or not), with no restrictions on concomitant pharmacological 
or psychological treatments; (3) placebo or non-antidepres-
sant anesthetic as a comparator; (4) ketamine therapy at a 
fixed dose (single or repeated administration—if repeated 
administration was studied results reported at least 2 weeks 
after the start of repeated dosing), with no restriction on 
the ketamine regimen used (e.g., dose or route); (5) evalu-
ation of depression severity based on a validated scale; (6) 
English-language papers. Studies were excluded based on 
the following criteria: (1) trials conducted in the context of 
electroconvulsive therapy (ECT) and surgery; (2) patients 
with “narrow” (e.g., postpartum depression) or secondary 
depression diagnoses (e.g., vascular depression); (3) keta-
mine used in an ascending dose; (4) duplicate studies. Data 
reported only in abstract form (with no associated full text) 
were rejected due to the lack of detailed information about 
methodology, population, and results. Nonrandomized as 
well as uncontrolled open-label studies and case reports 
were not included.
Data extraction and outcome measure
Data extracted by the first author (J.K.) were verified by 
the second author (A.M.M.). The primary outcome was 
a change from baseline in depression severity scores on 
depression scales such as the Hamilton Depression Rating 
Scale (HDRS) and/or the Montgomery–Åsberg Depression 
Rating Scale (MADRS) at the following time points: (1) 
day 1 (24 h); day 3 ([21] reported data for day 4); day 7 
after a single administration; (2) 2–4 weeks after the start 
of repeated dosing. The above time points were also used to 
assess response to treatment and remission. The following 
data were also extracted: population characteristics, study 
design, details of intervention and regimen, and definition 
of outcomes. If different doses of intravenous (IV) ketamine 
were analyzed in the study, the results for the dose of 0.5 mg/
kg were considered, as a recent meta-analysis has shown a 
lower antidepressant effect of very low doses of ketamine 
(0.1–0.4 mg/kg IV) [22]. For trials with a crossover design, 
results from the first period prior to the crossover were 
searched in published Cochrane meta-analyses [17, 18] or 
were requested from the authors of primary studies. Miss-
ing data were calculated from graphs independently by two 
authors and searched in clinical trials registry (www.clini 
caltr ials.gov).
Data analysis
Potential sources of bias were identified for each trial, using 
the criteria recommended in the Cochrane Handbook [23]. 
For continuous outcomes, the standardized mean difference 
(SMD) between ketamine and comparator with 95% con-
fidence intervals (CIs) was calculated. SMD was used as 
the included studies measured depressive symptoms in dif-
ferent psychometric scales. For dichotomous outcomes, the 
odds ratio (OR) with 95% CIs was calculated. The random 
effects model for both dichotomous and continuous vari-
ables was applied, because it has the highest generalizability 
for empirical examination of summary effect measures in 
meta-analyses [24]. Statistical significance was defined at a 
p value of less than 0.05. The results were presented as forest 
plots, using Review Manager v.5.3 and Microsoft Excel®. 
Sensitivity analysis was scheduled for the primary outcome 
as leave-one-study-out and exclusion of crossover trials if 
data regarding the first period before the crossover were not 
obtained. Subgroup analysis was planned for TRD, ketamine 
as monotherapy and as add-on to ongoing antidepressant 




The electronic searches yielded 1418 items after duplicates 
were removed. The selection of titles and abstracts resulted 
in 61 potentially relevant articles, of which 41 were excluded 
due to the reasons presented in Fig. 1. Finally, 20 studies 
described in 21 references met the predefined inclusion 
criteria. Of the 20 included studies, 16 trials investigating 
the clinical effects of a single-dose ketamine and 4 assess-
ing the effects of repeated administration were suitable for 
quantitative synthesis (meta-analysis). The flow of informa-
tion through the different phases of the systematic review is 
shown in Fig. 1. The methodology and main characteristics 
of patients involved in each RCT are described in Table 2. 
Potential sources of bias are summarized in Fig. 2.
Single doses: effects on depression severity scores 
over time
Based on pooled data from the included studies, single-
dose ketamine results in a significant reduction of depres-
sion severity scores at 24 h (SMD = − 0.89 [95% CI − 1.24; 
− 0.53]; p < 0.00001; test for heterogeneity:  Chi2 = 24.71; 
df = 11; p = 0.01;  I2 = 55%), 3–4  days (SMD =− 0.76 
[95% CI − 0.99; − 0.53]; p < 0.00001; test for heteroge-
neity:  Chi2 = 7.94; df = 10; p = 0.64; I2 = 0%), and 7 days 
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(SMD = − 0.38 [95% CI − 0.74; − 0.03]; p = 0.04; test for 
heterogeneity:  Chi2 = 22.75; df = 10; p = 0.01; I2 = 56%) in 
comparison with placebo, with the largest effect at 24 h 
postadministration (Fig. 3). The sensitivity analysis after 
the exclusion of studies for which data relating to the period 
before the crossover were not obtained [25, 26] showed that 
the observed effect was not markedly affected; however, 
the statistical difference was lost for 7 days. The forest plot 
for all time points and results of the sensitivity analysis are 
presented in Fig. 3 and Table 3. Leave-one-out analyses 
showed a more pronounced reduction of depression sever-
ity scores at 24 h (SMD = − 0.98 [95% CI − 1.21; − 0.74]; 
p < 0.00001; test for heterogeneity:  Chi2 = 9.43; df = 10; 
p = 0.49; I2 = 0%) and 7 days (SMD = − 0.50 [95% CI − 0.74; 
− 0.27]; p < 0.0001; test for heterogeneity:  Chi2 = 8.95; 
df = 9; p = 0.44; I2 = 0%) after exclusion of the study by 
Downey et al. [27], which showed no antidepressant effects 
of ketamine vs. control. Ketamine administration was shown 
to improve mostly emotional symptoms. Its effects on the 
individual HDRS/MDRS symptoms reported in the primary 
RCTs are presented in Table 4.
Single doses: effects on response and remission 
rates over time
In included RCTs, response was mostly defined as ≥ 50% 
reduction in Depression Severity Score from baseline 
(≥ 45% in [28]), while remission, as MADRS Score ≤ 10. 
Pooled results of 12 RCTs providing data on the 24-h 
response rate showed a low treatment effect on response 
(OR = 5.64 [95% CI 3.23; 9.85]; p < 0.00001; test for hetero-
geneity:  Chi2 = 8.89, df = 11; p = 0.63; I2 = 0%). Moreover, 
the effect of treatment on response was not consistent with 
the pooled data of a reduction in depression severity scores 
over time. While continuous outcomes showed the largest 
effect at 24 h postadministration, pooled ORs for response 
at 24 h was similar to those at 3–4 days (OR = 5.13 [95% CI 
2.90; 9.05]; p < 0.00001) and 7 days (OR = 5.71 [95% CI 
2.48; 13.16]; p < 0.0001) (Fig. 4). Leave-one-out analyses 
showed that after exclusion of a study involving patients 
with suicidal thoughts [29], the pooled OR for response at 
24 h (OR = 8.05 [95% CI 4.24; 15.30]; p < 0.00001) (Fig. 4) 
corresponded with results of the meta-analysis showing the 
most pronounced reduction in depressive symptoms (vs. 
controls) at 24 h postadministration. Of note, the response 
rate at 24 h postadministration was the only data reported 
by Grunebaum et al. [29] that were useful for meta-analysis, 
and the meta-analysis of any other outcomes did not con-
found with the results of this trial.
Pooled data showed a significant difference in remis-
sion in favor of ketamine over the control group at 24 h, 
3–4 days, and 7 days postadministration (Fig. 5). Although 
the pooled ORs for remission at day 7 were higher than those 
reported at 24 h and 3–4 days, sensitivity analyses revealed 
no marked difference after exclusion of each single trial, 
showing that the overall results were not driven by one study. 
As the remission rate remained consistent throughout the 
time points, it can be suggested that ketamine efficacy could 
be more stable and longer in early remitters than in early 
responders.
Single doses: a subgroup analysis
Subgroup analyses showed significant advantages of keta-
mine over controls in reducing depressive symptoms from 
24 h to 7 days postadministration in treatment-resistant 
patients and when ketamine was used as add-on to ongo-
ing antidepressant treatment and from 24 h to 3–4 days 
when ketamine was used as monotherapy (Table 3). The 
Fig. 1  PRISMA flow diagram 
for selection of studies identi-
fied in the systematic review
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most pronounced effect favoring ketamine over controls was 
observed in patients with TRD (Fig. 6). Ketamine produced 
also a significant reduction of depression severity scores 
from 24 h to 7 days (vs. controls) in unipolar depression. In 
bipolar depression, between-group differences were signifi-
cant at 24 h and 3 days postadministration; however, only 
two RCTs assessing the antidepressant effects of ketamine in 
patients exclusively with bipolar depression were included 
[8, 9]. Detailed data of all subgroup analyses are reported 
in Table 3.
Subgroup analyses were also performed to assess the 
influence of the control arm (placebo or active control—
midazolam) on the antidepressant effect size of ketamine. In 
four studies, midazolam was used in a control group; how-
ever, the results of individual meta-analyses were based on 
no more than two studies owing to limited available data for 
the time points analyzed. The advantages of ketamine over 
control in reducing depressive symptoms were shown both 
at 24 h and 3–4 days in placebo-controlled trials and only 
at 24 h postadministration in midazolam-controlled trials, 
with no significant difference at 7 days, regardless of control 
group (Table 3). Similarly, in midazolam-controlled trials, 
the pooled OR for response at 24 h was less pronounced 
(OR = 4.09 [95% CI 1.58; 10.54]) when compared with 
pooled data from all included RCTs (see Fig. 4), even after 
exclusion of the results of Grunebaum et al. [29] (OR = 6.00 
[95% CI 2.45; 14.70]) due to the reasons described earlier. 
The above data are consistent with higher response rates at 
24 h in midazolam-control arms (11–28%) than placebo-
control arms (0–6%), reported in primary studies included 
in the meta-analysis.
Repeated doses
Among the four identified RCTs of repeated ketamine 
administration, we searched for the results reported for the 
last observation during the randomized phase of each study. 
That was 3 weeks in the studies by Ionescu et al. [30] and 
Domany et al. [31], and 4 weeks in the study by Singh et al. 
[32]. However, Singh et al. [32] reported that most patients 
from placebo groups crossed to ketamine treatment after 
day 15 according to the predefined protocol (due to lack of 
efficacy). Therefore, data reported at day 15 (2 weeks) of 
the randomized phase were included in the meta-analysis. 
Arabzadeh et al. [33] reported efficacy results for as long as 
6 weeks; however, as patients in this study newly initiated 
sertraline therapy, only 2-week data would not be biased by 
the onset of sertraline antidepressant effects [34]. As a result, 
data after 2–3 weeks of repeated ketamine administration 
from particular studies were available for the meta-analysis. 
Singh et al. [32] reported that the twice- and thrice-weekly 
ketamine dosing regimens used in the study were equally 
effective in sustaining the antidepressant response; however, 
Fig. 2  Risk of bias summary: review authors’ judgements about each 
risk of bias item for each included study
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a separate meta-analysis was performed for both treatment 
regimens.
Pooled data showed a significant reduction of depres-
sion severity scores at 2–3 weeks of repeated ketamine 
administration in comparison with placebo (Fig. 7). How-
ever, as in the case of single doses, leave-one-out analyses 
showed that exclusion of the study by Ionescu et al. [30], 
involving patients with suicidal thoughts, resulted in a 
more pronounced reduction of depression severity scores 
at 2–3 weeks of repeated ketamine administration (vs. 
controls) (Fig. 7), comparable to the effect size observed 
24 h after single administration. It should be mentioned 
that both Grunebaum et al. [29] and Ionescu et al. [30] 
Fig. 3  Effects of single-dose ketamine on depression rating scale at 24 h, 3–4 days, and 7 days
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study involved patients with suicidal ideation, that in the 
latter were chronic (≥ 3 months).
As presented in Figs.  8 and 9, the pooled data of 
response and remission after excluding patients with 
suicidal thoughts [30] showed a significant difference in 
favor of ketamine over placebo at 2–3 weeks of repeated 
dosing.
Discussion
Due to the very promising results of the original study [6], 
the antidepressant effects of ketamine have been exten-
sively studied in the last years and some important and 
very recent RCTs in this field have been published between 
the years 2017 and 2019. The results of our meta-analysis 
are the most current and comprehensive pooled data of 
RCTs investigating single or repeated ketamine adminis-
tration in adult patients with unipolar and bipolar depres-
sion. We attempted to answer the question whether anti-
depressant effects of single ketamine administration could 
be maintained during repeated ketamine treatment based 
on aggregated data from RCTs. Moreover, we aimed to 
fill the gap in the literature regarding prolonged ketamine 
exposure in patients with depression.
The meta-analysis of data for both continuous (depression 
severity scores) and dichotomous (response and remission 
rates) outcomes confirmed that significant efficacy advan-
tage of single-dose ketamine vs. control was observed from 
24 h to 7 days postadministration, with peak effects at 24 h 
and generally smaller-to-medium effects at 7 days. The 
results of our meta-analysis, which included also the most 
recent RCTs, are in line with previous meta-analyses [11, 
17–19, 35, 36]. Significant benefits of single-dose ketamine 
vs. control were generally consistent among the subgroup 
of patients with TRD (approximately 50% of TRD patients 
reported response at 24 h after ketamine administration vs. 
6% in control groups) when ketamine was used as mono-
therapy and as adjunctive to ongoing antidepressant therapy, 
as well as in unipolar and bipolar depression. However, most 
identified RCTs involved patients with unipolar depression, 
whereas only two studies were designed to assess the anti-
depressant effects of single-dose ketamine in patients with 
bipolar depression [8, 9] and none of the RCTs investigated 
repeated ketamine administration in bipolar disorder.
Primary studies as well as published meta-analyses 
showed that the effect of single-dose ketamine is short lived, 
and nearly all patients relapsed within 2 weeks postadmin-
istration [6–9, 11]. As patients with depression need long-
term antidepressant effects, it is crucial to establish a strat-
egy to maintain the antidepressant outcomes of ketamine 
for a longer time. Our results showed robust and significant 
advantages of serial ketamine administration over placebo 
at 2–3 weeks in terms of the reduction of depressive symp-
toms. Pooled data revealed a significant benefit of ketamine 
over placebo also in terms of response and remission, after 
exclusion of the study involving heavily pretreated patients 
with suicidal thoughts [30], due the reasons described below. 
As reported in included RCTs, antidepressant effects were 
maintained for about 1 week of follow-up after ketamine 
cessation [31, 32]. Although data from uncontrolled studies 
showed that most patients relapse after a few weeks (usu-
ally before the end of the third week) after cessation of even 
repeated ketamine treatment [12, 13, 15], a very recent RCT 
on intranasal esketamine showed a sustained improvement 
in the mean MADRS ratings over the 8-week follow-up after 
treatment cessation [16].
Although the antidepressant effects of ketamine have been 
known from many years, it is still unclear how ketamine elic-
its its effects in patients with depression. As ketamine is a 
Table 4  Ketamine effects on the individual HDRS/MADRS symptoms in primary RCTs
Study Scale Ketamine-treated patients
Berman et al. 2000 [6] HDRS-25 Significant improvement for items of depressed mood, suicidality, helplessness, worthlessness
Zarate et al. 2006 [7] HDRS-21 Significant improvement (time–drug interaction) for items of depressed mood, guilt, work and interests and 
psychic anxiety significant improvement (main effect for drug) for items of suicide, insomnia, general 
somatic symptoms, genital symptoms, and hypochondriasis deterioration of depersonalization or dereali-
zation from 40 to 110 min and motor retardation and gastrointestinal symptoms at 40 min (improvement 
in motor retardation at day 1)
Diazgranados et al. 
2010 [8]
MADRS Significant improvement for items of apparent sadness, reported sadness, inner tension, reduced appetite, 
concentration difficulties, lassitude, inability to feel, pessimistic thoughts
Zarate et al. 2012 [9] MADRS Significant improvement for items of apparent sadness, reported sadness, inner tension, concentration dif-
ficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts
Su et al. 2017 [70] HDRS-17 Significant differences observed for total HDRS score was due to changes on emotional symptoms (somatic 
anxiety, psychological anxiety, guilt and delusions, loss of interest, depressed mood) persisting throughout 
the study and rapid but short-lasting changes on atypical symptoms (reduced libido, psychomotor slowing, 
suicidality, psychomotor agitation, hypochondriasis) but not insomnia-related symptoms (energy/fatigabil-
ity, delayed sleep onset, midnocturnal awakening, early morning awakening)
554 J. Kryst et al.
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potent noncompetitive glutamatergic N-methyl-d-aspartate 
(NMDA) receptor antagonists that binds to the phencycli-
dine binding site [37], its antidepressant effects are partially 
glutamate dependent. It has been proposed that through 
blockade of NMDA receptors on GABAergic interneurons 
ketamine reduce GABAergic transmission, which increases 
glutamate release and enhances the activation of α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors. These actions induce a signaling cascade that 
through brain-derived neurotrophic factor (BDNF) release 
Fig. 4  Effects of single-dose ketamine on response rates at 24 h (sensitivity analysis after exclusion of the study by Grunebaum et  al. [29]), 
3–4 days, and 7 days
555Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression:…
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Fig. 5  Effects of single-dose ketamine on remission rates at 24 h, 3–4 days, and 7 days
Fig. 6  Meta-analysis results: 
time course of overall standard-
ized mean differences (SMD) 
between ketamine and control in 
major depression—a subgroup 
analysis (abbreviations, see 
Table 2)
556 J. Kryst et al.
1 3
and stimulation of mammalian target of rapamycin (mTOR) 
modifies the number and function of synaptic connections 
[38]. However, ketamine’s mechanism of action is more 
complex and includes also non-glutamatergic actions 
such as interactions with the monoaminergic system [39], 
potentiation of the inhibitory effects of GABA [40], and 
interactions with ion channels [41–43]. Ketamine has also 
antagonistic effect on cholinergic neurons [44]. Due to the 
complex mechanism of action, ketamine exerts multiple 
effects, including anesthetic, analgesic, antidepressant, and 
psychomimetic effects [45]. Different neuropharamacologi-
cal actions are also involved in rapid and prolonged effects 
of ketamine exposure. While immediate effects are mostly 
connected with neuromodulation more delayed actions are 
connected with changes in gene expression and neuroplas-
ticity. Given more complexity, different brain regions may 
be involved in the effects observed after single and repeated 
ketamine administration. Recent data have shown that single 
ketamine treatment of patients with TRD leads to increased 
regional cerebral blood flow (CBF) in the cingulate and pri-
mary and secondary visual areas [46]. On the other hand, 
repeated ketamine treatment leads to a decrease in regional 
CBF in the hippocampus and right insula [46], which was 
earlier reported on the basis of positron emission tomogra-
phy (PET) findings [47].
Considering the complexity of neuropharamacologi-
cal actions of ketamine, it is also interesting to discuss the 
selection of patients for inclusion in the analyzed RCTs, 
because patients with a high risk of suicide and concomi-
tant psychiatric diagnosis were excluded from most tri-
als. It cannot be ruled out that the antidepressant effects 
of ketamine differ in such specific subgroups of patients. 
Among the included RCTs, we found two studies (both on 
single-dose and repeated ketamine administration) in which 
the antidepressant effects of ketamine were very low [29, 
30]. Both studies involved patients with suicidal ideation, 
and although ketamine has established antisuicidal effects, 
its effects on depression and suicidal thoughts are at least 
Fig. 7  Effects of serial ketamine on depression rating scale at 2–3 weeks; data regarding twice-weekly (a) or thrice-weekly (b) dosing from the 
study by Singh et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]
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partially independent [29, 48]. As indicated by Grunebaum 
et al. [29], a reduction of suicidal ideation in patients with 
depression observed after a single ketamine infusion did 
not correspond with antidepressant effects. Other stud-
ies showed that adjunctive ketamine led to a reduction of 
suicidal ideation even in those patients whose depression 
did not remit [49, 50]. Of note, the results of another RCT 
involving patients with suicidal ideation also showed mod-
erate antidepressant effects compared with control after a 
single-dose ketamine administration [51]. The results of an 
open-label study suggested that also the elevated level of 
treatment resistance is a potential factor explaining the lack 
of response to ketamine [52]. In line with this, a study by 
Ionescu et al. [30], in which ketamine did not outperform 
placebo in terms of antidepressant (and, in contrast to earlier 
trials, also antisuicidal) efficacy, involved heavily pretreated 
patients (more than six failed medication trials and more 
than 40% of patients failed ECT). Similar discrepancies in 
ketamine efficacy were also reported in uncontrolled stud-
ies. While up to six ketamine infusions led to response in 
58%–68% of patients and remission in 42%–51% of patients 
[49, 53], the results of another study showed response and 
remission rates of 35.7% and 14.3%, respectively, despite an 
increase in ketamine dose to 0.75 mg/kg if the patient did 
not experience an improvement after the first 3 infusions 
of the 0.5 mg/kg dose [52]. As patients in the latter study 
were highly pretreated (the number of failed antidepressant 
trials ranged from 3 to 19), with 43% of patients failing pre-
vious ECT, this might have contributed to lower ketamine 
efficacy, as in the RCT by Ionescu et al. [30]. The discussed 
findings suggest that patients with suicidal ideation or those 
severely pretreated and resistant to multiple treatments may 
Fig. 8  Effects of serial ketamine on response at 2–3 weeks, data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study of Singh 
et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]
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benefit less from ketamine treatment in terms of antidepres-
sant effects or need higher doses to achieve antidepressant 
effects [52]. Future RCTs should recruit more heterogene-
ous populations to assess the impact of ketamine treatment 
on patient subgroups depending on baseline demographic 
data, comorbidities, and also use of various psychotropic 
medications. Of note, a recent uncontrolled clinical study 
confirmed high antidepressant efficacy of single ketamine 
infusion in patients with TRD who showed significant psy-
chiatric comorbidity, with the 24-h response and remission 
rates of 54% and 42%, respectively [54].
Although another RCT included in the meta-analysis 
did not show antidepressant effects of ketamine vs. control 
[27], there is no clear explanation for these results. First 
of all, a significant placebo response was noted at all time 
points, and, in contrast to other trials, Downey et al. [27] 
reported less dissociative effects of ketamine, which were 
correlated with its antidepressant response [55]. The trial 
was conducted in untreated ambulatory participants with 
mild-moderate depression, and it was the only study where 
ketamine was infused for 60 min. In all other included 
RCTs where IV ketamine was used, infusions lasted over 
30–40 min. However, the sessions of IV ketamine infusion 
as long as 100 min have been demonstrated to be effective 
in uncontrolled studies [14, 53].
Two of the RCTs investigating repeated ketamine 
administration used oral ketamine, and both of them con-
firmed that this route of administration was highly effec-
tive in amelioration of depressive symptoms at 2–3 weeks 
[31, 33]. Oral dosing of ketamine is a recognized route of 
administration in chronic pain management [56] and would 
be a more practical and acceptable delivery method than 
Fig. 9  Effects of serial ketamine on remission at 2–3 weeks, data regarding twice-weekly (a) or thrice-weekly (b) dosing from the study of Singh 
et al. [32]. Sensitivity analysis excluded data from the study by Ionescu et al. [30]
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IV administration, especially for long-term use in patients 
with depression. Although the antidepressant effects of 
ketamine have been most extensively studied with the IV 
route of administration, some previous reports support oral 
ketamine use in depressed patients. The first positive report 
on the antidepressant effects of oral ketamine comes from 
hospice patients [57–59]. Oral ketamine was also effective 
in improving depressive symptoms in patients with mild-
moderate depression and chronic pain in an RCT by Jafarinia 
et al. [60]. A recent retrospective series of TRD patients 
showed modest antidepressant efficacy of repeated oral keta-
mine; however, a relatively low starting dose of 50 mg every 
3 days was used in this study [61]. Although the optimal dos-
ing regimen and route of ketamine administration remain to 
be explored, the benefits are probably dose dependent in the 
range of 0.1–0.75 mg/kg when given IV [62]. The bioavail-
ability of oral ketamine is around 24% [63], but given the 
potential cumulative effects of repeated dosing and concerns 
about safety of prolonged administration, oral ketamine at 
a dose of 1 mg/kg thrice weekly seems to be effective and 
safe [31] and is now under investigation in an RCT including 
patients with MDD [64].
Limitations
This meta-analysis has several limitations, mostly discussed 
before. First of all, most studies in this review included small 
sample sizes. Heterogeneity was found with regard to the 
severity of depression in recruited patients, use of concomi-
tant medications (continuing or tapering antidepressant 
therapy), documented resistance to antidepressant drugs, 
as well as depression scale used to assess antidepressant 
effects. Co-prescribed drugs might have an influence on ket-
amine effects; however, no details on ongoing antidepressant 
treatment were provided in the identified studies. Initiation 
of new antidepressant therapy with a drug of the same class 
both in the active and control arm of an RCT could reduce 
the effect of background antidepressant therapy, and this 
strategy was used in phase III clinical trials of intranasal 
esketamine [65, 66].
Not all included studies reported data at all the time 
points prespecified in this review, and data regarding the 
first period of crossover from two trials were not obtained. 
Some studies had missing data that were obtained even-
tually from graphs or clinical trials registry. Performed 
subanalysis raised also the question of effective masking 
in RCTs on ketamine. The use of placebo as a control is 
a limitation because the integrity of the blinding may be 
compromised. Ketamine administration causes transitory 
perceptual and dissociative disturbances that could lead 
to functional unblinding in patients and raters. Already 
the first published study showing antidepressant effects 
of ketamine reported that patients were readily able to 
distinguish between ketamine and placebo, owing to 
ketamine’s psychoactive effects [6]. The results of our 
meta-analysis showed a larger reduction (vs. controls) in 
depressive symptoms after single ketamine administration 
in placebo-controlled than midazolam-controlled trials. 
However, even when the active comparator (midazolam) 
was used in a primary study, 77% of patients were able to 
guess the assignment to IV ketamine at a dose of 0.5 mg/
kg and around 37% were able to guess the assignment to 
midazolam [67]. As a result, some degree of functional 
unblinding may bias study outcomes in RCTs on keta-
mine, especially when placebo is used as control. Despite 
limitations, a large number of included studies as well 
as robust and generally consistent effects strengthen the 
results of the meta-analysis regarding single-dose keta-
mine. The main limitation regarding repeated ketamine 
administration is a relatively small number of studies with 
eligible data and their heterogeneity. As discussed above, 
those trials differ in terms of the route of ketamine admin-
istration and dosing regimen as well as the population 
included (highly pretreated patients with chronic suicidal 
ideation or patients with moderate to severe depression), 
which confused the results due to a possible difference in 
ketamine antidepressant effects in selected subgroups of 
patients. In one RCT where ketamine was used for accel-
eration of response to a newly initiated antidepressant, 
only data after 2 weeks of dosing could be used for the 
meta-analysis, as a recent meta-analysis showed that the 
onset of significant antidepressant effects of sertraline vs. 
placebo is observed in the third week at the earliest [34].
Conclusions
The rapid and robust antidepressant effects of single-dose 
ketamine in patients with TRD suggest that ketamine is a 
promising candidate for an effective therapy in patients 
who do not respond to conventional treatment. Our find-
ings showed that a single administration of ketamine 
reduces depressive symptoms and that the initial antide-
pressant effects of the drug are sustained during serial 
administration, with a significant efficacy advantage over 
placebo at 2–3 weeks. The most recent RCTs have shown 
that serial administration of oral ketamine has significant 
antidepressant effects in major depression. However, fur-
ther studies are needed to assess long-term antidepressant 
effects of ketamine and to establish the optimal dose and 
route of administration. Our meta-analysis also highlighted 
a need for RCTs that would establish the antidepressant 
effects of ketamine in a selected group of patients, because 
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highly pretreated individuals and those with suicidal idea-
tion and resistance to multiple treatment approaches may 
benefit less from the antidepressant effects of ketamine 
than the general population.
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